The local vascular effect of carbachol infused in the cerebral ventricles of the cat.
Explore the source record for details and available documents.
Animals↗
SEARCH · PubMed Health
Results for “Infusions, Intraventricular”
Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
Temporal effects of an infusion of dobutamine hydrochloride in horses anesthetized with halothane.
OBJECTIVE: To evaluate temporal hemodynamic effects of dobutamine in horses anesthetized with halothane. ANIMALS: 8 adult Thoroughbreds. PROCEDURE: Anesthesia was induced by i.v. administration of romifidine and ketamine and maintained using halothane in oxygen. After 60 minutes, dobutamine was administered i.v. for 60 minutes at 4 micrograms/kg of body weight/min. Measurements of left ventricular function were obtained by transesophageal echocardiography and cardiac catheterization. RESULTS: Mean, systolic, diastolic, aortic, pulmonary arterial, and left and right ventricular end-diastolic and systolic pressures, maximal rate of increase of intraventricular pressure (LVdp/dtmax), maximum acceleration (dv/dtmax) and velocity (Vmax) of aortic blood flow, cardiac output, and left ventricular velocity time integral were significantly increased, whereas left ventricular pre-ejection period and ejection time significantly decreased. Cardiac output, LVdp/dtmax, Vmax, and dv/dtmax increased throughout infusion. Heart rate was significantly less after 10 minutes and significantly greater at 60 minutes than before infusion. Supraventricular tachycardia developed in 2 horses. Cardiac output, LVdp/dtmax, Vmax, dv/dtmax, left ventricular and aortic systolic pressures, and mean aortic pressure had not returned to control values 30 minutes after infusion was discontinued. CONCLUSIONS: At this dosage, dobutamine did not achieve peak effect on many hemodynamic variables within 40 minutes of commencing infusion, and effects of 60-minute infusion persisted after infusion was discontinued. CLINICAL RELEVANCE: Dobutamine has a hemodynamic profile suited to treatment of low cardiac output in anesthetized horses; however, sustained administration may be associated with supraventricular tachycardia and a protracted time to peak effect.
Anesthesia, Inhalation↗
Dose-ranging studies of clofilium, an antiarrhythmic quaternary ammonium.
Clofilium, a new quaternary ammonium antiarrhythmic without apparent ganglion-blocking effect, was evaluated in 25 patients, 22 with a history of ventricular arrhythmias and three with paroxysmal supraventricular arrhythmias. The study, including programmed atrial and ventricular stimulation, was carried out before and after infusion of 20 to 240 micrograms/kg IV as a single dose. Continuous Holter monitoring was carried out the day before the study through the fourth day after study, and laboratory parameters were monitored for up to 2 wk. There were no changes in intra-atrial and intraventricular conduction times or in AH or HV intervals. There were increases in QT interval, atrial effective refractory period, and ventricular refractory period. The atrioventricular nodal effective refractory period was unchanged. No side effects were noted, nor were changes in blood pressure or laboratory parameters. Monitoring revealed no change in frequency of premature ventricular complexes between the 24 hr before drug infusion and the 96 hr thereafter. In one patient refractoriness of the His-Purkinje system was increased and in two patients atrial fibrillation converted to sinus rhythm after clofilium. Three patients had sustained ventricular tachycardia with programmed stimulation before clofilium infusion; none had more than three repetitive ventricular responses after it. Clofilium increases atrial and ventricular effective refractory period without changing conduction time and, despite no apparent change in premature ventricular complex frequency, it can abolish the ability to induce ventricular tachycardia by programmed stimulation and is also well tolerated.
Adult↗
Albumin infusion for low serum albumin in preterm newborn infants.
BACKGROUND: Intravenous albumin infusion to treat hypoalbuminaemia is used in intensive care nurseries. Hypoalbuminaemia occurs in a number of clinical situations including prematurity, the acutely unwell infant, respiratory distress syndrome (RDS), chronic lung disease (CLD), necrotising enterocolitis (NEC), intracranial haemorrhage, hydrops fetalis and oedema. Fluid overload is a potential side effect of albumin administration. Albumin is a blood product and therefore carries the potential risk of infection and adverse reactions. Albumin is also a scarce and expensive resource. OBJECTIVES: The primary objective was to assess whether albumin infusions, in preterm neonates with low serum albumin, reduces mortality and morbidity. A secondary objective was to assess whether albumin infusion is associated with significant side effects. SEARCH STRATEGY: Searches were made of MEDLINE from 1966 to April 2004, CINAHL from 1982 to April 2004 and the current Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library issue 1, 2004). Previous reviews (including cross references) and abstracts were also searched. SELECTION CRITERIA: All randomised controlled trials in which individual patients were allocated to albumin infusion versus control were included. Cross-over studies were excluded. Quasi randomised trials were excluded. Participants were preterm infants who had hypoalbuminaemia. Types of interventions included albumin infusion versus placebo (e.g. crystalloid) or no treatment. DATA COLLECTION AND ANALYSIS: The reviewers worked independently to search for trials for inclusion and to assess methodological quality. Studies were assessed using the following key criteria: blinding of randomisation, blinding of intervention, completeness of follow up and blinding of outcome measurement. MAIN RESULTS: Only two small studies were found for inclusion in this review and only one reported clinically relevant outcomes - it found no significant differences for our primary outcome measure of death (RR 1.5 [95% confidence interval 0.3 - 7.43]) or secondary outcome measures of intraventricular haemorrhage, patent ductus arteriosus, necrotising enterocolitis, bronchopulmonary dysplasia, duration of mechanical ventilation and duration of oxygen therapy. REVIEWERS' CONCLUSIONS: There is a lack of evidence from randomised trials to determine whether the routine use of albumin infusion, in preterm neonates with low serum albumin, reduces mortality or morbidity, and no evidence to assess whether albumin infusion is associated with significant side effects. There is a need for good quality, double-blind randomised controlled trials to assess the safety and efficacy of albumin infusions in preterm neonates with low serum albumin.
Albumins↗
Immune lesions of central noradrenergic neurons produced by antibodies to dopamine-beta-hydroxylase.
(1) Intraventricular injection of antibodies to dopamine-beta-hydroxylase (DBH) caused degeneration of central noradrenergic nerve terminals in rats and guinea-pigs. In rats it was necessary to infuse exogenous complement in the form of guinea-pig serum together with the anti-DBH, whereas in guinea-pigs the anti-DBH was effective on its own. Control animals were infused with equivalent amounts of non-immune serum and complement and showed no signs of degeneration other than in the region of the needle tract. (2) There was a loss of varicosities in most terminal fields of the noradrenergic projections and swollen distorted axons were seen in both ascending and descending noradrenergic pathways. Noradrenergic cell bodies in the locus coeruleus and subcoeruleus appeared unaffected. No histochemical changes were observed in dopaminergic neurons. (3) The ultrastructural changes in degenerating axons that were first identifided by fluorescence histochemistry included swelling, vacuolation, accumulation of dense cored vesicles, lysosome-like bodies and smooth membranous sacs. The surrounding neuropil appeared normal. (4) There was a significant depletion of noradrenaline in all regions of the rat brain ranging from 20% in the hypothalamus to 80% in the neocortex. Dopamine concentrations were unaffected. (5) These observations provide a new approach to the production of selective lesions in specific neurotransmitter pathways that could be extended to non-adrenergic neurones. They may also be useful as a model for the study of autoimmune diseases of the nervous system.
Animals↗
Brain energy metabolism during controlled reduction of cerebral perfusion pressure in severe head injuries.
OBJECTIVE: To study cerebral biochemical markers with intracerebral microdialysis and bedside analysis in patients with severe head injuries treated with a controlled reduction of cerebral perfusion pressure (CPP). DESIGN: Prospective observational study. SETTING: Neurological intensive care unit in a university hospital. PATIENTS: A consecutive series of 48 patients with severe head injuries and intracranial pressure (ICP) above 20 mmHg after conventional treatment. INTERVENTIONS: Reduction of CPP was attained with i. v. infusion of beta1-antagonist (metoprolol) and an alpha2-agonist (clonidine). One microdialysis catheter was inserted via a burr hole frontally to that used for the intraventricular catheter ("better" position). In 27 patients one or more catheters were inserted into cerebral cortex surrounding an evacuated focal contusion or underlying an evacuated haematoma ("worse" position). Perfusion rate was 0.3 microl/min and samples were taken every 30 or 60 min. The levels of glucose, pyruvate, lactate, glycerol and glutamate were analysed and displayed bedside. RESULTS: After initiation of treatment mean CPP decreased from 73 to 62 mmHg. During the first 96 h CPP was less than 60 mmHg and less than 50 mmHg during 30% and 8% of the time, respectively. The treatment was associated with a gradual normalisation of all biochemical markers in the "better" as well as the "worse" catheter position. CONCLUSION: The study shows that pharmacological decrease in CPP according to the "Lund concept" is associated with a normalisation of cerebral metabolism. The study also indicates that intracerebral microdialysis can be used for evaluation of new treatment strategies.
Adolescent↗
Spinal monoaminergic modulation of masculine copulatory behavior in the rat.
The sexual behavior of male rats receiving infusions of 5-HT, dopamine and noradrenaline intrathecally in the spinal cord of intracerebroventricularly (i.c.v.) in the lateral ventricle was observed. Intrathecal infusions of 5-HT and noradrenaline inhibited penile insertions and ejaculation, noradrenaline being the more potent of the amines. Dopamine was without effect. I.c.v. amine infusions impaired to various extents the masculine mating pattern, primarily by interfering with the males' tendency to approach the females. The facilitation of mating seen after intrathecal administration of the aminotetraline, 8-OH-DPAT, was more pronounced than that observed following its i.c.v. infusion.
8-Hydroxy-2-(di-n-propylamino)tetralin↗
Cannula for intracerebral administration of experimental substances.
Two reliable intracerebral cannulas, with a protective cap and a locking arrangement of the extension tube can be made from inexpensive regular and dental disposable needles and syringes. The preparation and use of these alternative cannula systems which enable the prolonged intracerebral infusion of experimental substances in unrestrained, freely moving animals is described.
Animals↗
Intracerebroventricular cholecystokinin A-receptor antagonist does not reduce satiation by endogenous CCK.
Suppression of sham feeding by exogenous CCK-8 or intraintestinal oleate infusion is attenuated by peripheral administration of the CCK-A receptor antagonist, devazepide, but not by the CCK-B antagonist, L365260. Likewise, systemically administered devazepide increases food intake by real feeding rats. These results suggest that endogenous CCK participates in the reduction of food intake by intestinal oleate and ingested food. Although originally categorized as a "peripheral" receptor subtype, the CCK-A receptor is also present in the brain. In an effort to examine whether devazepide acts in the brain or in the periphery to attenuate suppression of food intake by intraintestinal oleate, we injected devazepide into the lateral or fourth cerebral ventricles of intraintestinally infused, sham-fed rats. We also compared the ability of intracerebroventricular (i.c.v.) and intraperitoneal (i.p.) devazepide to elicit increased food intake in real feeding rats. Doses of devazepide that were sufficient to attenuate or abolish oleate-induced suppression of sham feeding, when administered i.p., failed to attenuate suppression of intake when administered i.c.v., i.p. devazepide also was more effective than i.c.v. devazepide for attenuation of the suppression of sham feeding by i.p. injection of exogenous CCK-8. Finally, i.c.v. devazepide was ineffective for increasing real food intake, whereas the same dose administered i.p. significantly increased food intake. Our results do not support participation of brain CCK-A receptors in the suppression of food intake by exogenous CCK, or by endogenous CCK released after intraintestinal oleate infusion, or food intake.
Animals↗
The effect of different volumes of fluid resuscitation on traumatic-hemorrhagic shock at high altitude in the unacclimated rat.
The effects of different volumes of fluid resuscitation on traumatic hemorrhagic shock in unacclimated rats to high altitude were investigated. Seventy-eight Wistar rats were transported to LaSa, Tibet, 3760 meters above sea level, and traumatic hemorrhagic shock was induced by right-femur fracture plus bleeding to 45 mmHg of mean arterial pressure (MAP) for 1 h under the anesthesia of sodium pentobarbital (40 mg/kg, i.p.). Experiments were conducted in two series. In series I, 36 rats were equally divided into six groups: sham-operated, untreated (traumatic shock without fluid infusion), and with lactated Ringer's resuscitation (LR) of 1.0, 1.5, 2.0 or 3.0 times the shed blood (1, 1.5, 2, 3 vol LR group). MAP, left intraventricular systolic pressure, the maximal change rate of intraventricular pressure rise or decline (+/-dp/dtmax), the maximal physiological velocity of contractile element shortening, and the area of left intraventricular pressure-dp/dt vector loop (Lo) were observed at 30, 60, 90, and 120 min and the blood gases were determined at 30 and 120 min after resuscitation. Meanwhile the survival time was observed after the observation period. In series II, 42 rats were used to observe the effects of different volumes of fluid resuscitation on water content of lung and brain and hematocrit. One and 1.5 vol LR resuscitation significantly lifted MAP, left intraventricular systolic pressure, +dp/dtmax, and Lo, partially improved the blood gases and significantly prolonged the survival time. Although 2 and 3 vol of LR resuscitation caused apparent hemodilution and lung edema, they only partially improved hemodynamic parameters. Meanwhile 2 and 3 vol of LR resuscitation decreased the survival time. These results suggest that 1 and 1.5 vol of LR resuscitation can effectively resuscitate traumatic hemorrhagic shock at high altitude. More than two volumes of LR resuscitation would deteriorate the resuscitation outcome.
Altitude↗
Magnesium--a profibrillatory or antifibrillatory drug depending on plasma concentration, heart rate and myocardial perfusion.
BACKGROUND: The opinions on the efficacy of magnesium as an antiarrhythmic drug vary considerably. The action of magnesium on vulnerability to fibrillation was therefore investigated in anaesthetized, open-chest pigs under different conditions as regards plasma concentration, heart rate and myocardial perfusion. METHODS: Vulnerability to fibrillation was assessed by electrical fibrillation threshold (EFT), measured with 100-ms duration diastolic impulses. These stimuli were delivered to the heart normally perfused, at a usual (90 and 120 beats/min) or accelerated (180 beats/min) rate. Vulnerability to fibrillation was also assessed at the high rate (180 beats/min) in the heart made ischaemic by complete occlusion of the left anterior descending coronary artery near its origin. EFT was then measured at the end of occlusion periods which were of increasing duration (30, 60, 90, 120 s). Monophasic action potential (MAP) duration, intraventricular conduction time, left ventricular dP/dt max (LVdP/dt max) and mean blood pressure were concurrently measured. RESULTS: In the absence of ischaemia, 5 mumol.kg-1.min-1 magnesium i.v. infusion, which raised plasma concentration to 1.78 +/- 0.14 mmol/L, lowered EFT, measured at the rate of 116 beats/min, from 14.0 +/- 1.1 to 6.8 +/- 1.0 mA (P < 0.001), without significant variation of the other parameters. Administered as previously or in a markedly higher dose (400 mumol.kg-1 loading dose and 10 mumol.kg-1.min-1 infusion) which raised plasma concentration up to 4.84 +/- 0.52 mmol/L, magnesium significantly influenced neither EFT nor MAP duration, reduced by the high rate (180 beats/min) to 6.2-6.7 mA and 212-220 ms respectively. Under the same conditions, at the same 180 beats/min rate, ischaemia brings about a fall of EFT, from 6.9 down to nearly 0 mA, with occurrence of fibrillation, in approximately 120 s. Magnesium failed to slow this fall and to delay the onset of fibrillation. In contrast, within the minutes following the end of occlusion, magnesium increased EFT to a great extent (from 7.1 +/- 0.4 to 13.5 +/- 0.7 mA, P < 0.001), with a significant prolongation of MAP duration (212 +/- 6 to 234 +/- 8 ms, P < 0.01). CONCLUSION: Magnesium may develop profibrillatory or antifibrillatory effects depending on plasma concentration, heart rate and myocardial perfusion.
Animals↗
Blockade of satiety factors by central injection of neuropeptide Y in sheep.
The ability of neuropeptide Y (NPY) to stimulate feed intake was tested in combination with two treatments known to depress feed intake in sheep. Six ewe and three wether lambs (mean BW = 40 kg) fitted with lateral cerebral ventricular guide cannulas and ruminal cannulas had free access to a nutritionally complete, pelleted diet. Balloons placed into the rumen were filled with either 0, 30 or 60 ml of water/kg BW and left in place for 6 h; intake was measured. Based on the decline in feed intake observed with increasing balloon volume in the rumen, Exp. 2 was designed to test effects of NPY injection (0 or 3.0 nmol) into the lateral cerebral ventricle and ruminal distension (0 or 35 ml/kg BW) for 6 h. During the 6-h test period, feed intake was depressed (P less than .05) by intraruminal balloon distension, but feed intake was increased by NPY injection (P less than .05); no interaction between NPY and distension was detected. Ruminal evacuation revealed that digesta occupied only 43% of the rumen's total volume capacity. Balloons occupied 14% of capacity, whereas meal size in control sheep following a 1.5-h fast equaled 7% of capacity. In Exp. 3, intraruminal infusion of 8 mmol/min of propionate depressed (P = .11) feed intake, whereas NPY injection enhanced (P less than .05) intake. There was no interaction between NPY and propionate infusion. In none of these experiments was cumulative feed consumption at 24 h influenced. We conclude that NPY is a versatile feeding stimulant. It promotes feed intake in feed-satiated, ruminally distended and propionate-infused sheep.
Animals↗
Effect of intraventricular sodium nitroprusside on cerebral hemodynamics and oxygenation in poor-grade aneurysm patients with severe, medically refractory vasospasm.
OBJECTIVE: Sodium nitroprusside (SNP) was recently suggested as a treatment for cerebral ischemia in patients with severe, medically refractory vasospasm after subarachnoid hemorrhage. In this study, we sought to objectify the effect on cerebral hemodynamics and oxygenation (PbrO2) when using intraventricular SNP as a last resort therapy in poor-grade patients with subarachnoid hemorrhage; severe, medically refractory vasospasm; and compromised cerebral blood flow. METHODS: Thirteen of 185 consecutive patients with subarachnoid hemorrhage developed severe, medically refractory vasospasm and were treated with intraventricular SNP. All of these patients' neurological conditions were classified as Hunt and Hess Grade IV. SNP doses ranged from 10 to 40 mg with single-dose treatment and from 2 to 8 mg/h with continuous infusion. Angiography or PbrO2 measurement was used to assess the treatment effects. RESULTS: In 6 of the 13 patients, SNP improved cerebral hemodynamics, as demonstrated by increased PbrO2 or decreased cerebral circulation time. Only 1 patient showed increased diameter of the spastic vessel, however. Maximum increase in PbrO2 ranged from 5 to 52 mmHg. Adverse effects were hypertension in five patients, vomiting in three patients, and cardiac arrhythmia in one patient. Cerebral infarctions caused by vasospasm occurred in 6 (46%) of the 13 patients. No differences between SNP responders and SNP nonresponders were noted. CONCLUSION: In patients with severe, medically refractory vasospasm, intraventricular SNP may improve PbrO2 and cerebral blood flow, but the effect is highly variable. On the basis of the improvements we observed in 6 of 13 patients, intraventricular SNP administration is justified as a last resort therapy in patients with cerebral ischemia and impending infarction. Our findings suggest that SNP may be more effective when initiated early and administered continuously.
Adult↗
Locomotor effects of ethanol and acetaldehyde after peripheral and intraventricular injections in Swiss and C57BL/6J mice.
Several studies have suggested that acetaldehyde, the first product of ethanol metabolism, is involved in the locomotor stimulant effects of ethanol in mice, although it has never been formally tested whether acetaldehyde injected directly into the brain of mice has stimulant properties. Recently, it was also shown in rats that both ethanol and acetaldehyde can induce opposite locomotor effects according to the route of administration. Whereas peripheral administrations of ethanol and acetaldehyde induced locomotor depressant effects, their infusions directly into the brain produced locomotor stimulation. The aim of the present study was to characterize in mice the locomotor effects of ethanol and acetaldehyde injected either peripherally by the intraperitoneal route or centrally into the brain ventricles. Additionally, the effects of ethanol and acetaldehyde were compared in two strains of mice known for their differential sensitivity to the locomotor effects of ethanol, namely Swiss and C57BL/6J mice. Ethanol induced a biphasic effect on locomotor activity in Swiss mice, with stimulant effects at low to moderate doses and depressant effects at higher doses. Such a profile of effects was observed whatever the route of administration, peripheral or central. In C57BL/6J mice, ethanol only induced monophasic depressant effects. In this mouse strain, no evidence of the stimulant effects of ethanol was found after either an i.p. or an i.c.v. administration of ethanol. In contrast to ethanol, acetaldehyde yielded only depressant effects in both strains of mice after both peripheral and central administrations. These results indicate that the route of administration does not alter the locomotor effects of ethanol and acetaldehyde in mice. Additionally, the present study shows that the stimulant properties of acetaldehyde, even after direct infusion into the brain, are not as obvious as previously speculated.
Acetaldehyde↗
New delivery systems in pain management.
Technologic innovations have led to the development of new delivery systems in pain management. Prolonged-release morphine, implanted reservoirs, and external and internal infusion pumps are now employed to improve pain management techniques. These advances have allowed entry to previously inaccessible or difficult-to-enter sites such as the intravenous, subcutaneous, epidural, intrathecal, and intraventricular routes. The role of the nurse is paramount in applying these new technologies to pain control. The nurse must employ sound pain-management principles when choosing the route and delivery system that will meet the patient's needs. Nurses are responsible for implementation of the therapy, patient education, ongoing assessment, management of side effects, and evaluation of the effectiveness of the technique. Future innovations will lead to further advances in pain management techniques. As integral members of the health care team, nurses must be involved in the clinical research and evaluation of these new therapies. Advanced technology and supportive nursing care can then be united to ensure optimal pain control for our patients.
Analgesia↗
Chronic intracerebroventricular infusion of angiotensin II.
Explore the source record for details and available documents.
Angiotensin II↗
[Changes of myocardial dynamics in early stage of burn and effect of rapid fluid replacement in delayed resuscitation].
OBJECTIVE: To investigate the changes in myocardial dynamics in early phases of burn shock of dogs and the effects of rapid fluid infusion in delayed resuscitation. METHODS: Twelve mongrel dogs were randomly divided into control (n=6) and burn (n=6) groups. The dogs in burn group were subjected to 35% total body surface area (TBSA) III degree burn and were resuscitated with lactate Ringer's solution 6 hours postburn. The volumes and rates of fluid infusion were controlled basically on the urinary output of 1.0 mlxkg(-1)xh(-1) and cardiac output (CO) of 70%-80% of pre-burn values. The mean arterial pressure (MAP), left ventricular systolic pressure (LVSP), maximum rate of intraventricular pressure rise/down (+/-dp/dt max) and cardiac index (CI) were determined at 0.5, 1,2, 6, 7, 8, 10 and 24 hours postburn. RESULTS: The MAP, LVSP, +/-dp/dt max and CI were significantly lowered from their baseline and those of control group at 0.5 hour postburn, and they kept declining until 6 hours postburn. They showed a tendency of elevation and reached or approached the levels of that in control group within 2 hours of resuscitation, and the differences were not significant between the two groups 4 hours after burn (all P>0.05). The amount of infusion fluid within the first 4 hours of resuscitation was (3.63+/-0.99) ml/kg per 1% TBSA. CONCLUSION: The myocardial dynamics is depressed in the early stage of burn, the effective way to improve it is to infuse a large amount of fluid rapidly when resuscitation is delayed.
Animals↗
[Electrophysiological effects of the new antiarrhythmic drug flecainide (R 818) in man (author's transl)].
The electrophysiological effects of the new antiarrhythmic drug Flecainide (R 818) was tested in altogether 27 patients with and without disturbances of sinus node function and intraventricular conduction. Flecainide was given intravenously in a dose of 1 mg/kg and 2 mg/kg. Constant "therapeutic" plasma levels were reached by application of 1 mg/kg as a bolus and an additional infusion of 1 mg/kg during the test period of 20 min. The drug had no significant effects on sinus node function even in patients with sinus node dysfunction tested so far. Intracardiac conduction time was prolonged within all compartments of the heart in a dose-dependent manner. After bolus injection of 1 mg/kg, the HRA-A interval lengthened by 10.4%, the A-H interval by 13.5%, the H-V time by 15.7% and the V-RVA interval by 29.1% of the control value. In addition, the QRS complex widened by 8.1%. After 2 mg/kg Flecainide the HRA-A interval was prolonged by 9.0%, the A-H interval by 24.4%, the H-V time by 40.2%, and the V-RVA interval by 16.5% of the control value. The QRS complex widened by 24.2%. In contrast, there was only a small and often insignificant increase in the refractoriness of the different compartments of the heart (5-15% increase of the control value). In two patients with bundle branch block, a higher degree A-V block distal the H potential occurred after 2 mg/kg Flecainide. These electrophysiological effects may explain some antiarrhythmic actions of Flecainide. In addition, possible side effects of the drug can be assessed. In patients with intraventricular conduction defects the drug should be used with caution especially when given iv in higher doses.
Adult↗